{"DataElement":{"publicId":"2222045","version":"1","preferredName":"Support Treatment Agent Current Course Administered Type","preferredDefinition":"the type of support agent administered during the current course.","longName":"S_TX_AGT_CU_CR_AD_TP","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2222036","version":"1","preferredName":"Support Treatment Agent Current Course Administered","preferredDefinition":"information related to the support treatment agent administered during current course.","longName":"SU_TX_AGT_CU_CRS_ADM","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2222028","version":"1","preferredName":"Support Therapy Agent","preferredDefinition":"Support; approval; moral, psychological, physical, or financial aid or assistance.:An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.:An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI)","longName":"C37902:C15368:C1708","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Support","conceptCode":"C37902","definition":"Moral, psychological, physical, or financial aid or assistance; approval.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Therapy","conceptCode":"C15368","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5483D12-9A7D-7230-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-26","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-04-26","modifiedBy":"ONEDATA","dateModified":"2005-04-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2222029","version":"1","preferredName":"Current Course Administered","preferredDefinition":"Occurring in or belonging to the present time.:A period of protocol-prescribed activity or intervention.:Given.","longName":"C25471:C25379:C25382","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Current","conceptCode":"C25471","definition":"Occurring in or belonging to the present time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Course","conceptCode":"C25379","definition":"Passage through time; duration; a systematic or/and orderly succession; a sequence, e.g. course of treatment; a mode of action or behavior; natural development, typical manner of proceeding.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5483D12-9A83-7230-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-26","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-04-26","modifiedBy":"ONEDATA","dateModified":"2005-04-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F54516A5-2481-25D2-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-26","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-04-26","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2222041","version":"1","preferredName":"Support Agent Type","preferredDefinition":"the type of support therapy agents administered.","longName":"SUPP_AGT_TP","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":"4","maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Antibiotics","valueDescription":"Antibiotic","ValueMeaning":{"publicId":"2574589","version":"1","preferredName":"Antibiotic","longName":"2574589","preferredDefinition":"(an-tih-by-AH-tik) A drug used to treat infections caused by bacteria and other microorganisms.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Antibiotic","conceptCode":"C258","definition":"Substances naturally produced by microorganisms or their derivatives that selectively target microorganisms not humans. Antibiotics kill or inhibit the growth of microorganisms by targeting components of the microbial cell absent from human cells, including bacterial cell walls, cell membrane, and 30S or 50S ribosomal subunits. These substances are used in the treatment of bacterial and other microbial infections.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F06A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-26","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-04-26","modifiedBy":"ONEDATA","dateModified":"2005-04-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F5483D12-9ABA-7230-E034-0003BA3F9857","beginDate":"2005-04-26","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-04-26","modifiedBy":"CAMPBELB","dateModified":"2005-04-26","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2559653","version":"1","preferredName":"Other","longName":"2559653","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B612-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2023-12-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F5AB5316-FD7E-519F-E034-0003BA3F9857","beginDate":"2005-04-26","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-04-26","modifiedBy":"ONEDATA","dateModified":"2005-04-26","deletedIndicator":"No"},{"value":"GCSF","valueDescription":"GCSF","ValueMeaning":{"publicId":"2574591","version":"1","preferredName":"GCSF","longName":"2574591","preferredDefinition":"GCSF","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F06C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-26","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-04-26","modifiedBy":"CAMPBELB","dateModified":"2005-04-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F5AB5316-FD81-519F-E034-0003BA3F9857","beginDate":"2005-04-26","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-04-26","modifiedBy":"ONEDATA","dateModified":"2005-04-26","deletedIndicator":"No"},{"value":"Antidiarrheal","valueDescription":"Antidiarrheal","ValueMeaning":{"publicId":"2574592","version":"1","preferredName":"Antidiarrheal","longName":"2574592","preferredDefinition":"Antidiarrheal","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F06D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-26","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-04-26","modifiedBy":"CAMPBELB","dateModified":"2005-04-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F5AB5316-FD85-519F-E034-0003BA3F9857","beginDate":"2005-04-26","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-04-26","modifiedBy":"ONEDATA","dateModified":"2005-04-26","deletedIndicator":"No"},{"value":"Erythropoetin","valueDescription":"Erythropoetin","ValueMeaning":{"publicId":"2574593","version":"1","preferredName":"Erythropoetin","longName":"2574593","preferredDefinition":"Erythropoetin","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F06E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-26","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-04-26","modifiedBy":"CAMPBELB","dateModified":"2005-04-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F5AB5316-FD89-519F-E034-0003BA3F9857","beginDate":"2005-04-26","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-04-26","modifiedBy":"ONEDATA","dateModified":"2005-04-26","deletedIndicator":"No"},{"value":"Antiemetics","valueDescription":"Antiemetics","ValueMeaning":{"publicId":"2582482","version":"1","preferredName":"Antiemetics","longName":"2582482","preferredDefinition":"Antiemetics","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0F3F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-12-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-12-13","modifiedBy":"SHIDED","dateModified":"2006-12-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2480258A-832E-0BDC-E044-0003BA3F9857","beginDate":"2006-12-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-12-13","modifiedBy":"ONEDATA","dateModified":"2006-12-13","deletedIndicator":"No"},{"value":"Blood or blood products","valueDescription":"Blood or blood products","ValueMeaning":{"publicId":"2574594","version":"1","preferredName":"Blood or blood products","longName":"2574594","preferredDefinition":"Blood or blood products","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F06F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-26","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-04-26","modifiedBy":"CAMPBELB","dateModified":"2005-04-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2480258A-8340-0BDC-E044-0003BA3F9857","beginDate":"2006-12-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-12-13","modifiedBy":"ONEDATA","dateModified":"2006-12-13","deletedIndicator":"No"},{"value":"Bisphosphonates","valueDescription":"BISPHOSPHONATES","ValueMeaning":{"publicId":"2563589","version":"1","preferredName":"BISPHOSPHONATES","longName":"2563589","preferredDefinition":"BISPHOSPHONATES","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C572-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-12-04","endDate":null,"createdBy":"CVALMONT","dateCreated":"2002-12-04","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2DC7A8A2-FC6A-230D-E044-0003BA3F9857","beginDate":"2007-04-10","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-04-10","modifiedBy":"ONEDATA","dateModified":"2007-04-10","deletedIndicator":"No"},{"value":"Warfarin","valueDescription":"Warfarin","ValueMeaning":{"publicId":"2573141","version":"1","preferredName":"Warfarin","longName":"2573141v1.00","preferredDefinition":"A synthetic anticoagulant. Warfarin inhibits the regeneration of vitamin K1 epoxide and so the synthesis of vitamin K dependent clotting factors, which include Factors II, VII, IX and X, and the anticoagulant proteins C and S. This inhibition results in a sequential depression of Factors VII, IX, X and II activities. Vitamin K is an essential cofactor for the post ribosomal synthesis of the vitamin K dependent clotting factors. The vitamin promotes the biosynthesis of gamma-carboxyglutamic acid residues in these proteins which are essential for biological activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Warfarin","conceptCode":"C945","definition":"A synthetic anticoagulant. Warfarin inhibits the regeneration of vitamin K1 epoxide and so the synthesis of vitamin K dependent clotting factors, which include Factors II, VII, IX and X, and the anticoagulant proteins C and S. This inhibition results in a sequential depression of Factors VII, IX, X and II activities. Vitamin K is an essential cofactor for the post ribosomal synthesis of the vitamin K dependent clotting factors. The vitamin promotes the biosynthesis of gamma-carboxyglutamic acid residues in these proteins which are essential for biological activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EAC2-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-02-09","modifiedBy":"CLOHNES","dateModified":"2023-08-04","changeDescription":null,"administrativeNotes":"8/4/23 Added missing concepts per cleanup activities cjl.","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2DC7A8A2-FC76-230D-E044-0003BA3F9857","beginDate":"2007-04-10","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-04-10","modifiedBy":"ONEDATA","dateModified":"2007-04-10","deletedIndicator":"No"},{"value":"Aspirin","valueDescription":"ASPIRIN","ValueMeaning":{"publicId":"2562499","version":"1","preferredName":"ASPIRIN","longName":"2562499","preferredDefinition":"ASPIRIN","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C130-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-10-02","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-10-02","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2DC7A8A2-FC81-230D-E044-0003BA3F9857","beginDate":"2007-04-10","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-04-10","modifiedBy":"ONEDATA","dateModified":"2007-04-10","deletedIndicator":"No"},{"value":"Heparin","valueDescription":"Heparin","ValueMeaning":{"publicId":"2567254","version":"1","preferredName":"Heparin","longName":"2567254","preferredDefinition":"A sulfur-rich glycosaminoglycan with anticoagulant property. Heparin binds to antithrombin III to form a heparin-antithrombin III complex. The complex binds to and irreversibly inactivates thrombin and other activated clotting factors, such as factors IX, X, XI, and XII, thereby preventing the polymerization of fibrinogen to fibrin and the subsequent formation of clots.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Heparin","conceptCode":"C539","definition":"A sulfur-rich glycosaminoglycan with anticoagulant property. Heparin binds to antithrombin III to form a heparin-antithrombin III complex. The complex binds to and irreversibly inactivates thrombin and other activated clotting factors, such as factors IX, X, XI, and XII, thereby preventing the polymerization of fibrinogen to fibrin and the subsequent formation of clots.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D3C3-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-14","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-14","modifiedBy":"CURTIST","dateModified":"2011-04-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2DC7A8A2-FC8C-230D-E044-0003BA3F9857","beginDate":"2007-04-10","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-04-10","modifiedBy":"ONEDATA","dateModified":"2007-04-10","deletedIndicator":"No"},{"value":"Low Molecular Weight Heparin","valueDescription":"Low molecular weight heparin","ValueMeaning":{"publicId":"2573140","version":"1","preferredName":"Low molecular weight heparin","longName":"2573140","preferredDefinition":"Low molecular weight heparin","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EAC1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-02-09","modifiedBy":"CAMPBELB","dateModified":"2005-02-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2DC7A8A2-FC9E-230D-E044-0003BA3F9857","beginDate":"2007-04-10","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-04-10","modifiedBy":"ONEDATA","dateModified":"2007-04-10","deletedIndicator":"No"},{"value":"NSAIDS","valueDescription":"NSAID","ValueMeaning":{"publicId":"2574387","version":"1","preferredName":"NSAID","longName":"2574387","preferredDefinition":"NSAID","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EFA0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-11","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-04-11","modifiedBy":"SHIDED","dateModified":"2005-04-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2DC7AB6C-7A07-2195-E044-0003BA3F9857","beginDate":"2007-04-10","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-04-10","modifiedBy":"ONEDATA","dateModified":"2007-04-10","deletedIndicator":"No"},{"value":"Epoetin","valueDescription":"Epoetin Alfa","ValueMeaning":{"publicId":"2576817","version":"1","preferredName":"Epoetin Alfa","longName":"2576817","preferredDefinition":"A colony-stimulating factor that is made in the laboratory. It increases the production of red blood cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Epoetin Alfa","conceptCode":"C2695","definition":"A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine human erythropoietin (EPO). Produced primarily by cells of the peritubular capillary endothelium of the kidney in response to hypoxia, circulating EPO binds to EPO receptors on the surface of committed erythroid progenitors in the bone marrow resulting in their replication and maturation into functional erythrocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F91E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3A03FC2D-3A30-1DAE-E044-0003BA3F9857","beginDate":"2007-09-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-09-13","modifiedBy":"ONEDATA","dateModified":"2007-09-13","deletedIndicator":"No"},{"value":"GM-CSF","valueDescription":"GM-CSF","ValueMeaning":{"publicId":"2563567","version":"1","preferredName":"GM-CSF","longName":"2563567","preferredDefinition":"GM-CSF","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C55C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-11-06","endDate":null,"createdBy":"CVALMONT","dateCreated":"2002-11-06","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3A03FC2D-3A3B-1DAE-E044-0003BA3F9857","beginDate":"2007-09-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-09-13","modifiedBy":"ONEDATA","dateModified":"2007-09-13","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2177853","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"Type","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C16D625D-02B6-1907-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-07-09","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-07-09","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5483D12-9AA1-7230-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-26","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-04-26","modifiedBy":"SHIDED","dateModified":"2011-04-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811831","version":"1","longName":"Breast","context":"CTEP"}]},{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811963","version":"1","longName":"Treatment","context":"CTEP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Were supporting agents given","type":"Preferred Question Text","description":"Were supporting agents given during this cycle?","url":null,"context":"CTEP"},{"name":"CRF Text","type":"Alternate Question Text","description":"Were supporting agents given at any point during protocol treatment","url":null,"context":"CTEP"}],"origin":"CALGB CRF:Cancer and Leukemia Group B Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"F5AB447A-A07D-53B9-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-26","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-04-26","modifiedBy":"SHIDED","dateModified":"2009-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}